Physician profile
Ronald Shockley
NPI 1275511263
$13,466.46
in general payments reported to CMS, 2019-2025
28 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,490 · 2020: $2,628 · 2021: $2,601 · 2022: $2,326 · 2023: $1,395 · 2024: $1,977 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,241 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,241.04 |
| Education | $180.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $2,738.32 | 2019-2022 | |
| Viiv Healthcare Company | $2,123.80 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Melinta Therapeutics, LLC | $1,755.81 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Merck Sharp & Dohme LLC | $1,349.53 | 2019-2025 | Pifeltro, Dificid, Zerbaxa |
| Gilead Sciences, INC. | $1,137.64 | 2019-2025 | Yeztugo, Veklury |
| Abbvie INC. | $1,117.52 | 2019-2025 | Dalvance, Avycaz, Mavyret |
| Shionogi INC | $569.23 | 2021-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $546.35 | 2019-2025 | Nuzyra |
| Allergan, INC. | $527.61 | 2019-2020 | |
| Astellas Pharma US INC | $397.75 | 2019-2024 | Cresemba |
| Janssen Biotech, INC. | $342.63 | 2019-2022 | |
| Janssen Products, LP | $188.00 | 2021-2022 | |
| Theratechnologies INC. | $153.39 | 2019-2022 | |
| Insmed, INC. | $106.70 | 2020-2025 | Arikayce |
| Cumberland Pharmaceuticals, INC. | $67.50 | 2019-2023 | Vibativ |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $54.22 | 2022-2023 | Rebyota |
| La Jolla Pharmaceutical Company | $51.39 | 2021-2024 | Xacduro |
| Biomerieux INC | $46.57 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Vyera Pharmaceuticals, LLC | $21.81 | 2019 | |
| Mylan Specialty L.P. | $21.74 | 2019 | |
| Mylan Institutional INC. | $20.69 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $18.40 | 2020 | |
| Tactile Systems Technology INC | $17.65 | 2024 | Flexitouch Plus, Entre Plus |
| Redhill Biopharma INC. | $17.33 | 2021 | |
| Organogenesis INC. | $16.52 | 2024 | |
| Napo Pharmaceuticals INC | $15.88 | 2023 | Mytesi |
| Next Science LLC | $14.00 | 2023 | Xperience, Blastx, Surgx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Shockley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.